SynthesisFrontiers in pharmacology2019
Pharmacologic Approaches for the Management of Apathy in Neurodegenerative Disorders.
Synthesis in Frontiers in pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- Repetitive transcranial magnetic stimulation for apathy in patients with neurodegenerative conditions, cognitive impairment, stroke, and traumatic brain injury: a systematic review.Frontiers in psychiatry · 2023Pooled it
- Apathy Through History: A Disorder at the Crossroads of Psychiatry and Neurology.Neuropsychology review · 2026Review
- Exploring apathy components and their relationship in cognitive decline: insights from a network cross-sectional study.BMC psychology · 2025Article
- Exploring shared therapeutic targets for Alzheimer's disease and glioblastoma using network pharmacology and protein-protein interaction approach.Frontiers in chemistry · 2025Article
- Neuroprotective Effect ofBiology · 2024Article
- Treatment of Apathy in Parkinson's Disease and Implications for Underlying Pathophysiology.Journal of clinical medicine · 2024Review
- Distinguishing apathy from depression: A review differentiating the behavioral, neuroanatomic, and treatment-related aspects of apathy from depression in neurocognitive disorders.International journal of geriatric psychiatry · 2023Review
- Anticholinergic effect of resveratrol with vitamin E on scopolamine-induced Alzheimer's disease in rats: Mechanistic approach to prevent inflammation.Frontiers in pharmacology · 2023Article
- The importance of a multidimensional approach to the preclinical study of major depressive disorder and apathy.Emerging topics in life sciences · 2022Article
- Associations, overlaps and dissociations between apathy and fatigue.Scientific reports · 2022Article
- [Effect of Virtual Reality Program for Alleviating Behavioral and Psychological Symptoms of Dementia Patients].Journal of Korean Academy of Nursing · 2022Article
- Semiology and determinants of apathy across neurodegenerative motor disorders: A comparison between amyotrophic lateral sclerosis, Parkinson's and Huntington's disease.Frontiers in aging neuroscience · 2022Article
- The Effect of Reminiscence Therapy Using Virtual Reality on Apathy in Residential Aged Care: Multisite Nonrandomized Controlled Trial.Journal of medical Internet research · 2021Article
- S-Equol mitigates motivational deficits and dysregulation associated with HIV-1.Scientific reports · 2021Article
- Virtual reality intervention to improve apathy in residential aged care: protocol for a multisite non-randomised controlled trial.BMJ open · 2021Article
- Using Virtual Reality to Improve Apathy in Residential Aged Care: Mixed Methods Study.Journal of medical Internet research · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Apathy is one of the most frequent behavioral disturbances in many neurodegenerative disorders and is known to have a negative impact on the disease progression, particularly in Alzheimer's disease. Therapeutic options are currently limited and non-pharmacological approaches should constitute first line treatments. Pharmacological agents likely to reduce apathy levels are lacking. The objective of the present article is to review recent pharmacological treatments for apathy in neurodegenerative disorders. The Pubmed database was searched with a particular focus on articles published as of January 2017. Current main levels of evidence have been reported so far with cholinergic, glutamatergic and dopaminergic agents to reduce levels of apathy, despite several conflicting results. Treatment duration and samples sizes may have however decreased the validity of previous results. Ongoing studies involving more participants/treatment duration or distinct neural pathways may provide new insights in the treatment of apathy in neurodegenerative disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.